Reminder of Class Action Lawsuit for Nektar Therapeutics Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NKTR?
Source: Globenewswire
- Class Action Notification: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action are not required to pay any upfront fees, as attorney fees will be collected through a contingency fee arrangement, allowing investors to seek compensation without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses once the true information was disclosed.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its success and resource advantages in this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 72.960
Low
102.00
Averages
123.43
High
165.00
Current: 72.960
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action Lawsuit for Nektar Therapeutics Investors
- Class Action Notification: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action are not required to pay any upfront fees, as attorney fees will be collected through a contingency fee arrangement, allowing investors to seek compensation without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses once the true information was disclosed.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its success and resource advantages in this field.
See More
Faruqi & Faruqi Investigates Nektar Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Nektar Therapeutics for potential violations of securities laws between February 26, 2025, and December 15, 2025, urging affected investors to reach out to discuss their legal options.
- Trial Results Failure: Nektar's December 16, 2025 press release revealed that the REZOLVE-AA trial failed to achieve statistical significance, causing its stock price to drop by $4.14, or 7.77%, closing at $49.16 per share, indicating a severe loss of investor confidence in the company's prospects.
- False Statement Allegations: The complaint alleges that Nektar and its executives failed to adhere to applicable instructions and protocol standards during the trial, likely leading to significant negative impacts on the trial's results, thus rendering public statements materially false and misleading at all relevant times.
- Lead Plaintiff Role: The court-appointed lead plaintiff must be the investor with the largest financial interest in the relief sought, and Faruqi & Faruqi encourages anyone with information, including whistleblowers and former employees, to contact the firm to provide additional insights.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Issue: According to the complaint, Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial findings, while the company overstated the integrity of the trial in its public statements.
- Investor Losses: When the market learned the truth about Nektar, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, potentially leading to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultation for investors worldwide, encouraging affected shareholders to join the lawsuit for compensation, emphasizing that investors are not represented by an attorney until the class action is certified.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: A class action against Boston Scientific Corporation (NYSE:BSX) alleges that during the period from July 23, 2025, to February 3, 2026, the company failed to disclose the unsustainable growth rate of its U.S. electrophysiology segment, misleading investors and potentially leading to significant losses.
- Eos Energy Issues: Eos Energy Enterprises (NASDAQ:EOSE) faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging that the company could not achieve necessary production ramp-up and that its battery line downtime exceeded industry norms, negatively impacting market performance and investor confidence.
- Soleno Therapeutics Risks: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is accused in a class action from March 26, 2025, to November 4, 2026, of concealing significant safety concerns related to its DCCR clinical trial, which could lead to higher risks for patients post-launch, affecting the company's reputation and market outlook.
- Nektar Therapeutics Violations: Nektar Therapeutics (NASDAQ:NKTR) is implicated in a class action for the period from February 26, 2025, to December 15, 2025, for not adhering to applicable standards in the REZOLVE-AA trial, which may significantly impact trial results and further erode investor confidence.
See More
NEKTAR THERAPEUTICS: WEDBUSH BEGINS ANALYSIS WITH NEUTRAL RATING AND SETS PRICE TARGET AT $70
Company Overview: Nektar Therapeutics has received a neutral rating from Wedbush, indicating a cautious outlook on the company's performance.
Price Target: The price target set for Nektar Therapeutics is $70, suggesting potential growth based on current evaluations.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, indicating significant legal risks that could impact stock price and investor confidence.
- Trial Results Disappointment: On December 16, 2025, Nektar announced that its REZOLVE-AA clinical trial failed to achieve statistical significance, resulting in a stock price drop of $4.14, or 7.77%, highlighting potential mismanagement in clinical trial protocols that could undermine investor trust.
- False Statements Allegations: The lawsuit alleges that Nektar failed to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable instructions and standards, likely leading to significant negative impacts on trial results, thereby harming investor interests.
- Shareholder Action Recommendations: Shareholders are encouraged to contact Robbins LLP to participate in the class action as lead plaintiffs representing other shareholders, emphasizing the importance of corporate governance and shareholder rights protection, even for those who choose not to participate in the litigation.
See More
Reminder of Class Action Lawsuit for Nektar Therapeutics Investors
- Class Action Notification: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action are not required to pay any upfront fees, as attorney fees will be collected through a contingency fee arrangement, allowing investors to seek compensation without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses once the true information was disclosed.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its success and resource advantages in this field.
See More
Faruqi & Faruqi Investigates Nektar Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Nektar Therapeutics for potential violations of securities laws between February 26, 2025, and December 15, 2025, urging affected investors to reach out to discuss their legal options.
- Trial Results Failure: Nektar's December 16, 2025 press release revealed that the REZOLVE-AA trial failed to achieve statistical significance, causing its stock price to drop by $4.14, or 7.77%, closing at $49.16 per share, indicating a severe loss of investor confidence in the company's prospects.
- False Statement Allegations: The complaint alleges that Nektar and its executives failed to adhere to applicable instructions and protocol standards during the trial, likely leading to significant negative impacts on the trial's results, thus rendering public statements materially false and misleading at all relevant times.
- Lead Plaintiff Role: The court-appointed lead plaintiff must be the investor with the largest financial interest in the relief sought, and Faruqi & Faruqi encourages anyone with information, including whistleblowers and former employees, to contact the firm to provide additional insights.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Issue: According to the complaint, Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial findings, while the company overstated the integrity of the trial in its public statements.
- Investor Losses: When the market learned the truth about Nektar, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, potentially leading to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultation for investors worldwide, encouraging affected shareholders to join the lawsuit for compensation, emphasizing that investors are not represented by an attorney until the class action is certified.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: A class action against Boston Scientific Corporation (NYSE:BSX) alleges that during the period from July 23, 2025, to February 3, 2026, the company failed to disclose the unsustainable growth rate of its U.S. electrophysiology segment, misleading investors and potentially leading to significant losses.
- Eos Energy Issues: Eos Energy Enterprises (NASDAQ:EOSE) faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging that the company could not achieve necessary production ramp-up and that its battery line downtime exceeded industry norms, negatively impacting market performance and investor confidence.
- Soleno Therapeutics Risks: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is accused in a class action from March 26, 2025, to November 4, 2026, of concealing significant safety concerns related to its DCCR clinical trial, which could lead to higher risks for patients post-launch, affecting the company's reputation and market outlook.
- Nektar Therapeutics Violations: Nektar Therapeutics (NASDAQ:NKTR) is implicated in a class action for the period from February 26, 2025, to December 15, 2025, for not adhering to applicable standards in the REZOLVE-AA trial, which may significantly impact trial results and further erode investor confidence.
See More
NEKTAR THERAPEUTICS: WEDBUSH BEGINS ANALYSIS WITH NEUTRAL RATING AND SETS PRICE TARGET AT $70
Company Overview: Nektar Therapeutics has received a neutral rating from Wedbush, indicating a cautious outlook on the company's performance.
Price Target: The price target set for Nektar Therapeutics is $70, suggesting potential growth based on current evaluations.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, indicating significant legal risks that could impact stock price and investor confidence.
- Trial Results Disappointment: On December 16, 2025, Nektar announced that its REZOLVE-AA clinical trial failed to achieve statistical significance, resulting in a stock price drop of $4.14, or 7.77%, highlighting potential mismanagement in clinical trial protocols that could undermine investor trust.
- False Statements Allegations: The lawsuit alleges that Nektar failed to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable instructions and standards, likely leading to significant negative impacts on trial results, thereby harming investor interests.
- Shareholder Action Recommendations: Shareholders are encouraged to contact Robbins LLP to participate in the class action as lead plaintiffs representing other shareholders, emphasizing the importance of corporate governance and shareholder rights protection, even for those who choose not to participate in the litigation.
See More
